Sandoz Will Not Pursue US Advair Rival

Discontinuing Development Leads To $442m Impairment

 
• By Dave Wallace

Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.

Sportsman_Tired
Sandoz has given up on the race for a generic version of Advair Diskus • Source: Shutterstock

More from Strategy

More from Business